Progressive decrease of phosphocreatine, creatine and creatine kinase in skeletal muscle upon transformation to sarcoma

Autor: Patra, Subrata, Bera, Soumen, SinhaRoy, Soumya, Ghoshal, Sarani, Ray, Subhankar, Basu, Abhimanyu, Schlattner, Uwe, Wallimann, Theo, Ray, Manju
Přispěvatelé: Department of Biological Chemistry, Kolkata University, Department of Surgery, SSKM Hospital, Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Biology, Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich)-Institute of Cell Biology, Hamant, Sarah
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Phosphocreatine
Immunoblotting
Creatine Kinase
Mitochondrial Form
Adenocarcinoma
MESH: Neoplasms
Muscle Tissue
MESH: Phosphocreatine
MESH: Sarcoma
Experimental
Mice
Neoplasms
Muscle Tissue
Stomach Neoplasms
Creatine Kinase
BB Form
[SDV.BBM] Life Sciences [q-bio]/Biochemistry
Molecular Biology
Animals
Humans
MESH: Animals
MESH: Creatine Kinase
Mitochondrial Form
[SDV.BBM]Life Sciences [q-bio]/Biochemistry
Molecular Biology
RNA
Messenger
Muscle
Skeletal
Creatine Kinase
MESH: Mice
MESH: RNA
Messenger
MESH: Muscle
Skeletal
MESH: Humans
MESH: Creatine Kinase
MESH: Immunoblotting
MESH: Creatine
MESH: Adenocarcinoma
Creatine Kinase
MM Form
Sarcoma
MESH: Stomach Neoplasms
MESH: Creatine Kinase
BB Form
Creatine
Cell Transformation
Neoplastic
MESH: Cell Transformation
Neoplastic
MESH: Creatine Kinase
MM Form
MESH: Sarcoma
Disease Progression
MESH: Disease Progression
Sarcoma
Experimental
Colorectal Neoplasms
MESH: Colorectal Neoplasms
Zdroj: FEBS Journal
FEBS Journal, Wiley, 2008, 275 (12), pp.3236-47. ⟨10.1111/j.1742-4658.2008.06475.x⟩
ISSN: 1742-464X
1742-4658
DOI: 10.1111/j.1742-4658.2008.06475.x⟩
Popis: International audience; In vertebrates, phosphocreatine and ATP are continuously interconverted by the reversible reaction of creatine kinase in accordance with cellular energy needs. Sarcoma tissue and its normal counterpart, creatine-rich skeletal muscle, are good source materials to study the status of creatine and creatine kinase with the progression of malignancy. We experimentally induced sarcoma in mouse leg muscle by injecting either 3-methylcholanthrene or live sarcoma 180 cells into one hind leg. Creatine, phosphocreatine and creatine kinase isoform levels decreased as malignancy progressed and reached very low levels in the final stage of sarcoma development; all these parameters remained unaltered in the unaffected contralateral leg muscle of the same animal. Creatine and creatine kinase levels were also reduced significantly in frank malignant portions of human sarcoma and gastric and colonic adenocarcinoma compared with the distal nonmalignant portions of the same samples. In mice, immunoblotting with antibodies against cytosolic muscle-type creatine kinase and sarcomeric mitochondrial creatine kinase showed that both of these isoforms decreased as malignancy progressed. Expressions of mRNA of muscle-type creatine kinase and sarcomeric mitochondrial creatine kinase were also severely downregulated. In human sarcoma these two isoforms were undetectable also. In human gastric and colonic adenocarcinoma, brain-type creatine kinase was found to be downregulated, whereas ubiquitous mitochondrial creatine kinase was upregulated. These significantly decreased levels of creatine and creatine kinase isoforms in sarcoma suggest that: (a) the genuine muscle phenotype is lost during sarcoma progression, and (b) these parameters may be used as diagnostic marker and prognostic indicator of malignancy in this tissue.
Databáze: OpenAIRE
Externí odkaz: